Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Safety
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Aims & Objectives

The objective of this study was to conduct a systematic review of research pertaining to the COVID-19 vaccine and its association with neurological complications.

Methods

We performed a comprehensive search of the literature using Google Scholar, PubMed, and NCBI databases from December 2021 to December 2022. For Google Scholar, PubMed, and NCBI databases we used the following key search terms: “neurological adverse effects”, “COVID-19 vaccination”, “SARS-CoV-2”, CNS complications, and CNS adverse effects. Two reviewer authors individually searched and assessed the titles and abstracts of all articles. The third reviewer resolved the disagreement between them. Data were documented regarding title, study location, type of study, type of COVID-19 vaccine, type of neurological complications/adverse effects, and sample size.

Results

From our findings, it is confirmed that these neurological complications like Guillain-Barre syndrome (23.6%), Neuromyelitis Optica spectrum disorder (5.5%), Neuropathy (6.9%), Transverse Myelitis (8.3%) and Acute disseminated Encephalomyelitis (4.1%) are majorly affected in most of the people. The increase in risks associated with SARS-CoV-2 infection far outweighs any previously reported associations with vaccination.

Conclusion

We found no safety signal was observed between COVID-19 vaccines and the immune-mediated neurological events. Before assuming a causal relationship, the side effects of the COVID-19 vaccine should first be carefully examined to rule out known associated factors. Symptom onset was within two weeks of vaccination in the majority of cases; as such, this seems to be a high-risk period warranting vigilance.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863273931231121072231
2024-01-24
2025-04-24

  • From This Site

    /content/journals/cds/10.2174/0115748863273931231121072231
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. NagyA. AlhatlaniB. An overview of current COVID-19 vaccine platforms.Comput. Struct. Biotechnol. J.2021192508251710.1016/j.csbj.2021.04.06133936564
     [Google Scholar]
  2. who.intAvailable from: https://covid19.who.int/mapFilter=deaths (Accessed on: 13 Novr 2022).2022
  3. Al-ObaidiM.M.J. BahadoranA. WangS.M. ManikamR. RajuC.S. SekaranS.D. Disruption of the blood brain barrier is vital property of neurotropic viral infection of the central nervous system.Acta Virol.2018621162710.4149/av_2018_10229521099
     [Google Scholar]
  4. LiYC BaiWZ HashikawaT The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.J Med Virol2020926552555
     [Google Scholar]
  5. SriwastavaS. ShresthaA.K. KhalidS.H. ColantonioM.A. NwaforD. SrivastavaS. Spectrum of neuroimaging findings in post-COVID-19 vaccination: A case series and review of literature.Neurol. Int.202113462263910.3390/neurolint1304006134842783
     [Google Scholar]
  6. AbrahamG. BhalalaO.G. de BakkerP.I.W. RipattiS. InouyeM. Towards a molecular systems model of coronary artery disease.Curr. Cardiol. Rep.201416648810.1007/s11886‑014‑0488‑124743898
     [Google Scholar]
  7. SafaviF. GustafsonL. WalittB. LehkyT. DehbashiS. WieboldA. Neuropathic symptoms with SARS-CoV-2 vaccination.medRxiv2022
     [Google Scholar]
  8. GunawanP.Y. TiffaniP. LalisangL. Guillain-Barre syndrome following SARS-CoV-2 vaccination: A case report.Clin. Psychopharmacol. Neurosci.202220477778010.9758/cpn.2022.20.4.77736263653
     [Google Scholar]
  9. FinstererJ. Neurological side effects of SARS‐CoV‐2 vaccinations.Acta Neurol. Scand.202214515910.1111/ane.1355034750810
     [Google Scholar]
  10. IsmailI.I. SalamaS. A systematic review of cases of CNS demyelination following COVID-19 vaccination.J. Neuroimmunol.202236257776510.1016/j.jneuroim.2021.57776534839149
     [Google Scholar]
  11. RománG.C. GraciaF. TorresA. PalaciosA. GraciaK. HarrisD. Acute transverse myelitis (ATM): Clinical review of 43 patients with COVID-19-Associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222).Front. Immunol.20211265378610.3389/fimmu.2021.65378633981305
     [Google Scholar]
  12. HsiaoY.T. TsaiM.J. ChenY.H. HsuC.F. Acute transverse myelitis after COVID-19 vaccination.Medicina20215710101010.3390/medicina5710101034684047
     [Google Scholar]
  13. VogrigA. JanesF. GigliG.L. CurcioF. NegroI.D. D’AgostiniS. FabrisM. ValenteM. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination.Clin. Neurol. Neurosurg.202120810683910.1016/j.clineuro.2021.10683934325334
     [Google Scholar]
  14. LiS.Y. ChenH.H. LiuP.Y. ShiZ.Y. LinY.H. TsaiC.A. LinS.P. Case report of acute encephalitis following the AstraZeneca COVID‐19 vaccine.Int. J. Rheum. Dis.202225895095610.1111/1756‑185X.1437235748025
     [Google Scholar]
  15. RenemaneL. VrublevskaJ. CeraI. First episode psychosis following COVID-19 vaccination: A case report.Psychiatr. Danub.202234S8565936170703
     [Google Scholar]
  16. SuriV. PandeyS. SinghJ. JenaA. Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination.BMJ Case Rep.20211410e24581610.1136/bcr‑2021‑24581634607818
     [Google Scholar]
  17. KhanZ. KhattakA.A. RafiqN. AminA. AbdullahM. Interstitial lung disease and transverse myelitis: A possible complication of COVID-19 vaccine.Cureus2022142e2187510.7759/cureus.2187535273846
     [Google Scholar]
  18. ElaidouniG. ChetouaniZ. Manal merbouhC. BkiyarH. HousniB. Acute ischemic stroke after first dose of inactivated COVID-19 vaccine: A case report.Radiol. Case Rep.20221761942194510.1016/j.radcr.2022.02.08235392049
     [Google Scholar]
  19. Abu-AbaaM. DawoodG. ArshadH. JumaahO. LandauD. A possible case of autoimmune encephalitis after mRNA COVID-19 booster vaccine: A case report.Cureus20221411e3111810.7759/cureus.3111836479395
     [Google Scholar]
  20. BellucciM. GermanoF. GrisantiS. CastellanoC. TazzaF. MobiliaE.M. VisigalliD. NoviG. MassaF. RossiS. DurandoP. CabonaC. SchenoneA. FranciottaD. BenedettiL. Case report: Post-COVID-19 vaccine recurrence of guillain–barré syndrome following an antecedent parainfectious COVID-19–related GBS.Front. Immunol.20221389487210.3389/fimmu.2022.89487235924236
     [Google Scholar]
  21. ZlotnikY. GadothA. Abu-SalamehI. HorevA. NovoaR. IferganeG. Case report: Anti-LGI1 encephalitis following COVID-19 vaccination.Front. Immunol.20221281348710.3389/fimmu.2021.81348735069602
     [Google Scholar]
  22. GargR.K. MalhotraH.S. KumarN. PandeyS. PatilM.R. UniyalR. RizviI. Tumefactive demyelinating brain lesion developing after administration of adenovector-based COVID-19 vaccine: A case report.Neurol. India202270140941135263930
     [Google Scholar]
  23. BouattourN. HdijiO. SakkaS. FakhfakhE. MoallaK. DaoudS. FarhatN. DamakM. MhiriC. Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases.Neurol. Sci.202243275576110.1007/s10072‑021‑05733‑x34796417
     [Google Scholar]
  24. HanifF. SatitiS. SubagyaS. RetnowulanH. SubrontoY.W. MulyaD.P. Ar RochmahM. Progressive worsening of neurological manifestations in HIV-associated opportunistic central nervous system (CNS) infection patients after COVID-19 vaccinations: A possible co-incidence causality.Am. J. Case Rep.202223e93625710.12659/AJCR.93625735610955
     [Google Scholar]
  25. MoscaraL. TafuriS. GagliardiD. StefanizziP. Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in a subject affected by Shapiro’s syndrome: A case report.Hum. Vaccin. Immunother.2022186209414810.1080/21645515.2022.209414835763557
     [Google Scholar]
  26. CastiglioneJ.I. CrespoJ.M. LecchiniL. SilveiraF.O. LuisM.B. CottiN. SimisonC.J. AguirreF. PiedrabuenaM.A. AlonsoR.N. AzconaC.L. SosaP.S. MaldonadoE. BarrosoF. Bilateral facial palsy with paresthesias, variant of Guillain-Barré syndrome following COVID-19 vaccine: A case series of 9 patients.Neuromuscul. Disord.202232757257410.1016/j.nmd.2022.05.00335644722
     [Google Scholar]
  27. BramerS. JaffeY. SivagnanaratnamA. Vestibular neuronitis after COVID-19 vaccination.BMJ Case Rep.2022156e24723410.1136/bcr‑2021‑24723435667696
     [Google Scholar]
  28. AmjadM.A. HamidZ. PatelY. HusainM. SaddiqueA. LiaqatA. OchiengP. COVID-19 vaccine-induced parsonage-turner syndrome: A case report and literature review.Cureus2022145e2549310.7759/cureus.2549335783889
     [Google Scholar]
  29. FernandesJ. JaggernauthS. RamnarineV. MohammedS.R. KhanC. PandayA. Neurological conditions following COVID-19 vaccinations: Chance or association?Cureus2022142e2191910.7759/cureus.2191935155043
     [Google Scholar]
  30. UmezawaS. IokaK. AizawaS. TashiroY. YoshizawaK. First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2.Neurol. Sci.202344245145510.1007/s10072‑022‑06465‑236289118
     [Google Scholar]
  31. OharaH. ShimizuH. KasamatsuT. KajitaA. UnoK. LaiK.W. VellingiriB. SugieK. KinoshitaM. Cytotoxic lesions of the corpus callosum after COVID-19 vaccination.Neuroradiology202264102085208910.1007/s00234‑022‑03010‑y35809100
     [Google Scholar]
  32. LeeM.A. LeeC. ParkJ.H. LeeJ.H. Early-onset myasthenia gravis following COVID-19 vaccination.J. Korean Med. Sci.20223710e5010.3346/jkms.2022.37.e5035289135
     [Google Scholar]
  33. ScendoniR. PetrelliC. ScaloniG. LogulloF.O. Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine.Hum. Vaccin. Immunother.202117114093409610.1080/21645515.2021.195482634347563
     [Google Scholar]
  34. AlgahtaniH.A. ShirahB.H. AlwafiE. Acute cervical dystonia following the BNT162b2 mRNA COVID-19 vaccine.Clin. Neurol. Neurosurg.202221810730410.1016/j.clineuro.2022.10730435605509
     [Google Scholar]
  35. ZavariA. HamidabadN.M. HassanzadehM. Aseptic meningitis following AZD1222 COVID-19 vaccination.Am. J. Emerg. Med.202255225.e5225.e610.1016/j.ajem.2021.12.03534955313
     [Google Scholar]
  36. LiangH. CaoY. ZhongW. MaZ. LiuJ. ChenH. Miller-Fisher syndrome and Guillain–Barre syndrome overlap syndrome following inactivated COVID-19 vaccine: Case report and scope review.Hum. Vaccin. Immunother.2022186212575310.1080/21645515.2022.212575336315834
     [Google Scholar]
  37. DoiK. OharaY. OuchiT. SasakiR. MakiF. MizunoJ. Cervical transverse myelitis following COVID-19 vaccination.NMC Case Rep. J.20229014514910.2176/jns‑nmc.2022‑004535756190
     [Google Scholar]
  38. ThantH.L. MorganR. PaeseM.M. PersaudT. DiazJ. HurtadoL. Guillain-barré syndrome after Ad26.COV2.S vaccination.Am. J. Case Rep.202223e93527510.12659/AJCR.93527535157644
     [Google Scholar]
  39. LucaA. SquillaciR. TerravecchiaC. ContrafattoF. ReggioE. NicolettiA. ZappiaM. Pure sensitive chronic inflammatory axonal polyneuropathy following Pfizer COVID-19 vaccine.Neurol. Sci.20224321431143310.1007/s10072‑021‑05696‑z34734345
     [Google Scholar]
  40. PinzonR.T. HaryonoF.K. DarmawanN.E. SalikimM.A.M. VeronicaV. Acute dizziness and mental alteration associated with Moderna COVID-19 vaccine: A case report.BMC Neurol.202222132210.1186/s12883‑022‑02834‑836028809
     [Google Scholar]
  41. TatumP. Meralgia paresthetica mimic after Moderna COVID‑19 vaccine.Neurol. Sci.20234441159116110.1007/s10072‑022‑06257‑835871181
     [Google Scholar]
  42. Al-MashdaliA.F. AtaY.M. SadikN. Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: A case report.Ann. Med. Surg.20216910280310.1016/j.amsu.2021.10280334512961
     [Google Scholar]
  43. ChuangT.Y. BurdaK. TeklemariamE. AtharK. Tolosa-hunt syndrome presenting after COVID-19 vaccination.Cureus2021137e1679134513398
     [Google Scholar]
  44. ManeaM.M. DragoșD. EnacheI. SirbuA.G. TutaS. Multiple cranial nerve palsies following COVID‐19 vaccination—Case report.Acta Neurol. Scand.2022145225725910.1111/ane.1354834725821
     [Google Scholar]
  45. ConsoliS. DonoF. EvangelistaG. D’ApolitoM. TravagliniD. OnofrjM. BonanniL. Status migrainosus: A potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report.Neurol. Sci.202243276777010.1007/s10072‑021‑05741‑x34807361
     [Google Scholar]
  46. LeeS.M. HongJ.Y. KimS.Y. NaS.J. Ipsilateral radial neuropathy after COVID-19 mRNA vaccination in an immunocompetent young man.Yonsei Med. J.2022631096697010.3349/ymj.2022.003836168250
     [Google Scholar]
  47. VencesM.A. Araujo-ChumaceroM.M. CardenasE. CanalesD. AlvarezA. BarjaE. AlbujarM.F. Urrunaga-PastorD. Autoimmune encephalitis after BBIBP-CorV (Sinopharm) COVID-19 vaccination: A case report.BMC Neurol.202222142710.1186/s12883‑022‑02949‑y36376863
     [Google Scholar]
  48. AhmadH.R. TimmermansV.M. DakakniT. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination.Am. J. Case Rep.202223e93657410.12659/AJCR.93657435717556
     [Google Scholar]
  49. ShalabiF. LossosA. KarussisD. A case report of unilateral cervical lymphadenopathy and multiple cranial neuropathies following mRNA-COVID-19 vaccination.BMC Neurol.202222136910.1186/s12883‑022‑02900‑136163025
     [Google Scholar]
  50. ShyuS. FanH.T. ShangS.T. ChanJ.S. ChiangW.F. ChiuC.C. ChenM.H. ShyuH.Y. HsiaoP.J. Clinical manifestation, management, and outcomes in patients with COVID-19 vaccine-induced acute encephalitis: Two case reports and a literature review.Vaccines2022108123010.3390/vaccines1008123036016118
     [Google Scholar]
  51. RohillaR. KakkarA.K. DivyashreeK. MohindraR. SuriV. Recombinant protein subunit COVID‐19 vaccine‐induced Guillain‐Barré Syndrome in an adolescent: A case report.Br. J. Clin. Pharmacol.202389255656010.1111/bcp.1546635856283
     [Google Scholar]
  52. RayS. KamathV.V. Raju PA. KnR. NS. Fulminant reversible cerebral vasoconstriction syndrome in breakthrough COVID 19 infection.J. Stroke Cerebrovasc. Dis.202231210623810.1016/j.jstrokecerebrovasdis.2021.10623834915308
     [Google Scholar]
  53. NanatsueK. TakahashiM. ItayaS. AbeK. InabaA. A case of Miller Fisher syndrome with delayed onset peripheral facial nerve palsy after COVID-19 vaccination: A case report.BMC Neurol.202222130910.1186/s12883‑022‑02838‑435996074
     [Google Scholar]
  54. YuB.Y. CenL.S. ChenT. YangT.H. Bell’s palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell’s palsy: A case report.World J. Clin. Cases20219278274827910.12998/wjcc.v9.i27.827434621891
     [Google Scholar]
  55. KhokharF. KhanA. HussainZ. YuJ. Small fiber neuropathy associated with the moderna SARS-CoV-2 vaccine.Cureus2022146e2596910.7759/cureus.2596935812635
     [Google Scholar]
  56. Reyes-CapoD.P. StevensS.M. CavuotoK.M. Acute abducens nerve palsy following COVID-19 vaccination.J. AAPOS202125530230310.1016/j.jaapos.2021.05.00334044114
     [Google Scholar]
  57. NotghiA.A.A. AtleyJ. SilvaM. Lessons of the month 1: Longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination.Clin. Med.2021215e535e53810.7861/clinmed.2021‑047034507942
     [Google Scholar]
  58. MonteG. ProS. UrsittiF. FerilliM.A.N. MoaveroR. PapettiL. SforzaG. BracagliaG. VigevanoF. PalmaP. ValerianiM. Case report: A pediatric case of Bickerstaff brainstem encephalitis after COVID-19 vaccination and Mycoplasma pneumoniae infection: Looking for the culprit.Front. Immunol.20221398796810.3389/fimmu.2022.98796836032138
     [Google Scholar]
  59. AladdinY. ShirahB. New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine.J. Neuroimmunol.202135757762910.1016/j.jneuroim.2021.57762934153802
     [Google Scholar]
  60. SendaJ. AshidaR. SugawaraK. KawaguchiK. Acute Meningoencephalitis after COVID-19 vaccination in an adult patient with rheumatoid vasculitis.Intern. Med.202261101609161210.2169/internalmedicine.8815‑2135283382
     [Google Scholar]
  61. IntronaA. CaputoF. SantoroC. GuerraT. UcciM. MezzapesaD.M. TrojanoM. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?Clin. Neurol. Neurosurg.202120810688710.1016/j.clineuro.2021.10688734418708
     [Google Scholar]
  62. SalehM. ZimmermannJ. LehnenN.C. PötzschB. WellerJ.M. Late-onset vaccine-induced immune thombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis.J. Stroke Cerebrovasc. Dis.202231410631110.1016/j.jstrokecerebrovasdis.2022.10631135093626
     [Google Scholar]
  63. LohmannL. GlaserF. MöddelG. LünemannJ.D. WiendlH. KlotzL. Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: A case report.BMC Neurol.202222118510.1186/s12883‑022‑02698‑y35585528
     [Google Scholar]
  64. ČenščákD. UngermannL. ŠtětkářováI. EhlerE. Guillan-Barré syndrome after first vaccination dose against COVID-19: Case report.Acta Med. 202164318318610.14712/18059694.2021.3134779385
     [Google Scholar]
  65. YazdanpanahF. IranpourP. HaseliS. PoursadeghfardM. YarmahmoodiF. Acute disseminated encephalomyelitis (ADEM) after SARS- CoV-2 vaccination: A case report.Radiol. Case Rep.20221751789179310.1016/j.radcr.2022.03.01335355527
     [Google Scholar]
  66. ChenS. FanX.R. HeS. ZhangJ.W. LiS.J. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19.Neurol. Sci.20214293537353910.1007/s10072‑021‑05427‑434189662
     [Google Scholar]
  67. VegezziE. RavagliaS. BuongarzoneG. BiniP. DiamantiL. GastaldiM. PrunettiP. RognoneE. MarchioniE. Acute myelitis and ChAdOx1 nCoV-19 vaccine: Casual or causal association?J. Neuroimmunol.202135957768610.1016/j.jneuroim.2021.57768634392078
     [Google Scholar]
  68. PanholzerJ. KellermairL. EggersC. Hypoglossal nerve palsy after SARS-CoV-2 vaccination – report of two cases.BMC Neurol.202222141610.1186/s12883‑022‑02929‑236352369
     [Google Scholar]
  69. MaramattomB.V. MoiduF.M. VarikkottilS. SyedA.A. Cerebral venous sinus thrombosis after ChAdOx1 vaccination: The first case of definite thrombosis with thrombocytopenia syndrome from India.BMJ Case Rep.20211410e24645510.1136/bcr‑2021‑24645534706921
     [Google Scholar]
  70. FujikawaP. ShahF.A. BrafordM. PatelK. MadeyJ. Neuromyelitis optica in a healthy female after severe acute respiratory syndrome coronavirus 2 mRNA-1273 vaccine.Cureus2021139e1796110.7759/cureus.1796134660149
     [Google Scholar]
  71. MichalicováA. BhideK. BhideM. KováčA. How viruses infiltrate the central nervous system.Acta Virol.201761439340010.4149/av_2017_40129186956
     [Google Scholar]
  72. WuY XuX ChenZ DuanJ HashimotoK YangL Nervous system involvement after infection with COVID-19 and other coronaviruses.Brain Behav Immun.2020871822
     [Google Scholar]
  73. ZhangY. ZengG. PanH. LiC. HuY. ChuK. HanW. ChenZ. TangR. YinW. ChenX. HuY. LiuX. JiangC. LiJ. YangM. SongY. WangX. GaoQ. ZhuF. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.Lancet Infect. Dis.202121218119210.1016/S1473‑3099(20)30843‑433217362
     [Google Scholar]
  74. ChenL. CaiX. ZhaoT. HanB. XieM. CuiJ. ZhangJ. WangC. LiuB. LuQ. CuiF. Safety of global SARS-CoV-2 vaccines, a meta-analysis.Vaccines202210459610.3390/vaccines1004059635455344
     [Google Scholar]
  75. BettiniE. LocciM. SARS-CoV-2 mRNA vaccines: Immunological mechanism and beyond.Vaccines20219214710.3390/vaccines902014733673048
     [Google Scholar]
  76. FrancisA.I. GhanyS. GilkesT. UmakanthanS. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.Postgrad. Med. J.202298115938939410.1136/postgradmedj‑2021‑14065437066438
     [Google Scholar]
  77. PavordS. ScullyM. HuntB.J. LesterW. BagotC. CravenB. RampotasA. AmblerG. MakrisM. Clinical features of vaccine induced immune thrombocytopenia and thrombosis.N. Engl. J. Med.2021385181680168910.1056/NEJMoa210990834379914
     [Google Scholar]
  78. DuttaS. KaurR. CharanJ. BhardwajP. AmbwaniS.R. BabuS. GoyalJ.P. HaqueM. Analysis of neurological adverse events reported in VigiBase from COVID-19 vaccines.Cureus2022141e2137610.7759/cureus.2137635198288
     [Google Scholar]
  79. VaratharajA. ThomasN. EllulM.A. DaviesN.W.S. PollakT.A. TenorioE.L. SultanM. EastonA. BreenG. ZandiM. ColesJ.P. ManjiH. Al-Shahi SalmanR. MenonD.K. NicholsonT.R. BenjaminL.A. CarsonA. SmithC. TurnerM.R. SolomonT. KneenR. PettS.L. GaleaI. ThomasR.H. MichaelB.D. AllenC. ArchibaldN. ArkellJ. Arthur-FarrajP. BakerM. BallH. Bradley-BarkerV. BrownZ. BrunoS. CareyL. CarswellC. ChakrabartiA. ChoulertonJ. DaherM. DaviesR. Di Marco BarrosR. DimaS. DunleyR. DuttaD. EllisR. EverittA. FadyJ. FearonP. FisnikuL. GbinigieI. GemskiA. GilliesE. Gkrania-KlotsasE. GriggJ. HamdallaH. HubbettJ. HunterN. HuysA-C. IhmodaI. IspoglouS. JhaA. JoussiR. KalladkaD. KhalifehH. KooijS. KumarG. KyawS. LiL. LittletonE. MacleodM. MacleodM.J. MadiganB. MahadasaV. ManoharanM. MarigoldR. MarksI. MatthewsP. MccormickM. McinnesC. MetastasioA. Milburn-McNultyP. MitchellC. MitchellD. MorgansC. MorrisH. MorrowJ. Mubarak MohamedA. MulvennaP. MurphyL. NamushiR. NewmanE. PhillipsW. PintoA. PriceD.A. ProschelH. QuinnT. RamseyD. RoffeC. Ross RussellA. SamarasekeraN. SawcerS. SayedW. SekaranL. Serra-MestresJ. SnowdonV. StrikeG. SunJ. TangC. VranaM. WadeR. WhartonC. WiblinL. BoubriakI. HermanK. PlantG. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study.Lancet Psychiatry202071087588210.1016/S2215‑0366(20)30287‑X32593341
     [Google Scholar]
  80. HessD.C. EldahshanW. RutkowskiE. COVID-19-related stroke.Transl. Stroke Res.202011332232510.1007/s12975‑020‑00818‑932378030
     [Google Scholar]
  81. MauryA. LyoubiA. Peiffer-SmadjaN. de BrouckerT. MeppielE. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians.Rev. Neurol.20211771-2516410.1016/j.neurol.2020.10.00133446327
     [Google Scholar]
  82. GhiasiN. ValizadehR. ArabsorkhiM. HoseyniT.S. EsfandiariK. SadighpourT. JahantighH.R. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion.Immunopathologia Persa202172e3110.34172/ipp.2021.31
     [Google Scholar]
  83. SaeedB.Q. Al-ShahrabiR. AlhajS.S. AlkokhardiZ.M. AdreesA.O. Side effects and perceptions following Sinopharm COVID-19 vaccination.Int. J. Infect. Dis.202111121922610.1016/j.ijid.2021.08.01334384899
     [Google Scholar]
  84. GreinacherA. SchönbornL. SiegeristF. SteilL. PalankarR. HandtkeS. RederA. ThieleT. AurichK. MethlingK. LalkM. VölkerU. EndlichN. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).Semin. Hematol.20225929710710.1053/j.seminhematol.2022.02.00435512907
     [Google Scholar]
  85. AmaralM.E.A. ÁvilaL.R. AmaralB.M.F. NasserA.K.S. SilvaJ.P.M. TaveiraJ.H.A. Guillain-Barré syndrome associated with COVID-19: A systematic review.Res. Soc. Develop.20211015e19810152258510.33448/rsd‑v10i15.22585
     [Google Scholar]
  86. RaoS.J. KhuranaS. MurthyG. DawsonE.T. JazebiN. HaasC.J. A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine.J. Community Hosp. Intern. Med. Perspect.202111559760010.1080/20009666.2021.195428434567447
     [Google Scholar]
  87. RossoM. AnziskaY. LevineS.R. Acute transient encephalopathy after Moderna COVID-19 vaccine.Case Rep. Neurol.202214223123610.1159/00052376935702446
     [Google Scholar]
  88. LiuB.D. UgoliniC. JhaP. Two cases of post-Moderna COVID19 vaccine encephalopathy associated with nonconvulsive status epilepticus.Cureus2021137e1617210.7759/cureus.1617234367780
     [Google Scholar]
  89. MalhotraH.S. GuptaP. PrabhuV. Kumar GargR. DanduH. AgarwalV. COVID-19 vaccination-associated myelitis.QJM2021114859159310.1093/qjmed/hcab06933787891
     [Google Scholar]
  90. TanW.Y. Yusof KhanA.H.K. Mohd YaakobM.N. Abdul RashidA.M. LohW.C. BaharinJ. IbrahimA. IsmailM.R. Inche MatL.N. Wan SulaimanW.A. BasriH. HooF.K. Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: A case report.BMC Neurol.202121139510.1186/s12883‑021‑02427‑x34641797
     [Google Scholar]
/content/journals/cds/10.2174/0115748863273931231121072231
Loading
A Systematic Review of the COVID Vaccine's Impact on the Nervous System
Curr Drug Saf 20, 33 (2025); https://doi.org/10.2174/0115748863273931231121072231
/content/journals/cds/10.2174/0115748863273931231121072231
/content/journals/cds/10.2174/0115748863273931231121072231
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): acute disseminated encephalomyelitis; astrazeneca; CNS adverse effects; CNS complications; covaxin; COVID-19 vaccination; guillain-barre syndrome; johnson & johnson; moderna; Neurological adverse effects; neuropathy; Pfizer; SARS-CoV-2; sinopharm; sinovac; sputnik; transverse myelitis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test